image

Biopharmaceutical CMO Market Scope & Overview:

The Biopharmaceutical CMO Market size was valued at USD 30.22 billion in 2022 and is expected to reach USD 79.77 billion by 2030 with a growing CAGR of 12.9% over the forecast period of 2023-2030.

A company that offers manufacturing and related services to biopharmaceutical companies under a contract is known as a Contract Manufacturing Organisation (CMO) in the biopharmaceutical sector. An organisation that produces biologic pharmaceuticals, or complex medicinal items generated from living creatures such proteins, antibodies, and vaccines, is known as a biopharmaceutical CMO.

Biopharmaceutical CMO Market Revenue Analysis

To Get More Information on Biopharmaceutical CMO Market - Request Sample Report

Cell culture, fermentation, purification, formulation, and fill-finish procedures are all handled by a biopharmaceutical CMO. In order to guarantee the security and effectiveness of the biologic medications, these procedures need for specialised tools, cleanrooms, and strict quality control procedures. In the biopharmaceutical sector, adherence to regulatory requirements, such as Good Manufacturing Practises (GMP), is essential. To satisfy the demands of health authorities, a CMO must uphold high quality standards, create strong quality systems, and assure adherence to regulatory norms.

To support the production of biologic pharmaceuticals, biopharmaceutical CMOs invest in cutting-edge infrastructure and technologies. Specialized bioreactors, purification techniques, and analytical tools fall under this category. To ensure effective and dependable manufacturing, your team should have experience in process creation, optimisation, and scale-up.

Market Dynamics:

Driver :

  • The rise in the development in the Biopharmaceutical sector.

Thanks to advances in biotechnology and a growing emphasis on personalised medicine, the biopharmaceutical sector has been expanding significantly. For a variety of illnesses, such as cancer, autoimmune diseases, and uncommon genetic problems, biologic medications offer specialised treatments. The need for biologic medications is driven by the increasing occurrence of these diseases and the want for more potent therapies.

Restrain :

  • The struct regulatory rules which creating barrier for the Biopharmaceutical sector.  

The biopharmaceutical sector is heavily regulated, and adherence to the industry's strict regulations is essential. CMOs must adhere to the legal requirements put forth by regulatory bodies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). It can be difficult for CMOs to maintain compliance with changing laws and regulations as they change or become more complex.

Opportunity

  • The rising demand for the biologic therapies.

Due to biologic therapies success in treating a variety of disorders, there is a growing market for them. By supplying biopharmaceutical businesses with their manufacturing knowledge and capabilities, CMOs can profit from this expanding demand. CMOs can meet the growing demand for biologic pharmaceuticals by offering dependable and effective manufacturing services while also establishing long-term relationships with pharmaceutical firms.

Impact of Russia Ukraine War:

The supply chain for consumables, equipment, and raw materials used in biopharmaceuticals may be affected by the conflict. Conflict may cause delays or shortages of vital components required for the production of biopharmaceuticals if it disrupts economic relations or transportation routes between the two nations. CMOs that depend on vendors from either Russia or Ukraine may have trouble assuring a consistent supply of supplies.

Impact of Recession:

Budget restrictions during a recession may cause biopharmaceutical businesses to cut back on their investment in research and development (R&D). The quantity and size of projects that biopharmaceutical companies take on may be impacted by this, which may lead to a decline in the need for CMO services. CMOs may need to change their capacity and resource allocation in response to a slowdown in new project possibilities.

Key Market Segmentation

Source Outlook

  • Mammalian

  • Non- Mammalian

Service Outlook

  • Contract Manufacturing

  • Contact Research

Product Outlook

  • Biologics

  • Biosimilars

Biopharmaceutical CMO Market Segmentation Analysis

Do You Need any Customization Research on Biopharmaceutical CMO Market - Enquire Now

Regional Analysis:

North America is the region which will dominate the market the biopharmaceutical CMO market is heavily concentrated in North America, particularly the United States. The area has a developed healthcare system, a well-established biopharmaceutical industry, and a friendly regulatory environment. The need for CMO services is driven by the existence of several biopharmaceutical businesses and research facilities. High levels of technological advancement and competition, particularly the ability to manufacture cell and gene therapies, are market characteristics.

Europe is the region which will have the second large share because biopharmaceutical CMO market also has a substantial presence in Europe. Switzerland, Germany, and the United Kingdom, for example, have developed pharmaceutical businesses and CMOs. The region benefits from a strong regulatory environment, which includes the rules set forth by the European Medicines Agency (EMA), which regulate the production of biologic drugs. Academic research facilities and biotech clusters both encourage innovation and development along with the rising investment. Whereas APAC will be the region which will have the highest CAGR growth rate there are several factors which contribute to this growth the major ones include The market is expanding as a result of elements such a huge patient population, reduced production costs, improved regulatory frameworks, and government measures to support the biopharmaceutical industry. Additionally, the area provides prospects for CMOs that specialise in generic biologics and biosimilars.

Key Players

The major players are Lonza, Thermo Fisher Scientific, Cambrex Corporation, Catalent, Fujifilm, Siegfried Holding Ag, Samsung Biologics, AbbVie, Binex, Parexel international Corporation and others.

Cambrex Corporation-Company Financial Analysis

Company Landscape Analysis

Recent Developments:

Thermo Fisher Scientific – The introduction of Groundbreaking Mass Spectrometer to revolutionize Biological discovery.

Samsung Biologics – The strategic collaboration of Pfizer and Samsung biologics for long-term manufacturing of biosimilars portfolio.

Siegfried Holding Ag – The company has opened a new global development centre for drugs products in Barcelona.

Biopharmaceutical CMO Market Report Scope:

Report Attributes Details
Market Size in 2022  US$ 30.22 Bn
Market Size by 2030  US$ 79.77  Bn
CAGR   CAGR of 12.9% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Source Outlook (Mammalian, Non-Mammalian)
• By Service Outlook (Contract Manufacturing, Contact Research)
• By Product outlook (Biologics, Biosimilars)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Lonza, Thermo Fisher Scientific, Cambrex Corporation, Catalent, Fujifilm, Siegfried Holding Ag, Samsung Biologics, AbbVie, Binex, Parexel international Corporation
Key Drivers • The rise in the development in the Biopharmaceutical sector.
Market Opportunities • The rising demand for the biologic therapies.

 

Frequently Asked Questions

Ans : The Biopharmaceutical CMO Market size was valued at USD 12.91 billion in 2022 and is expected to reach at USD 32.90 billion by 2030, and grow at a CAGR of 12.4% over the forecast period of 2023-2030.

Ans : Budget restrictions during a recession may cause biopharmaceutical businesses to cut back on their investment in research and development (R&D).

Ans : APAC  is said to be  the region which will have the highest CAGR growth rate during the forecasted period because of the technological advancement in the healthcare industry in these regions.

Ans : Market is divided in three segments by Source Outlook, by Service outlook and by Product Outlook.

Ans : The rise in the development in the  Biopharmaceutical sector.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Biopharmaceutical CMO Market Segmentation By Source Outlook
8.1 Mammalian
8.2 Non- Mammalian

9. Biopharmaceutical CMO Market Segmentation By Service Outlook
9.1 Contract Manufacturing
9.2 Contact Research

10. Biopharmaceutical CMO Market Segmentation By Product Outlook
10.1 Biologics
10.2 Biosimilars

11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Biopharmaceutical CMO Market by Country
11.2.2North America Biopharmaceutical CMO Market by Source Outlook
11.2.3 North America Biopharmaceutical CMO Market by Service Outlook
11.2.4 North America Biopharmaceutical CMO Market by Product Outlook
11.2.5 USA
11.2.5.1 USA Biopharmaceutical CMO Market by Source Outlook
11.2.5.3 USA Biopharmaceutical CMO Market by Service Outlook
11.2.5.4 USA Biopharmaceutical CMO Market by Product Outlook
11.2.6 Canada
11.2.6.1 Canada Biopharmaceutical CMO Market by Source Outlook
11.2.6.3 Canada Biopharmaceutical CMO Market by Service Outlook
11.2.6.4 Canada Biopharmaceutical CMO Market by Product Outlook
11.2.7 Mexico
11.2.7.1 Mexico Biopharmaceutical CMO Market by Source Outlook
11.2.7.3 Mexico Biopharmaceutical CMO Market by Service Outlook
11.2.7.4 Mexico Biopharmaceutical CMO Market by Product Outlook
11.3 Europe
11.3.1 Europe Biopharmaceutical CMO Market by country
1.3.3.2 Europe Biopharmaceutical CMO Market by Source Outlook
11.3.3 Europe Biopharmaceutical CMO Market by Service Outlook
11.3.4 Europe Biopharmaceutical CMO Market by Product Outlook
11.3.5 Germany
11.3.5.1 Germany Biopharmaceutical CMO Market by Source Outlook
11.3.5.2 Germany Biopharmaceutical CMO Market by Service Outlook
11.3.5.3 Germany Biopharmaceutical CMO Market by Product Outlook
11.3.6 UK
11.3.6.1 UK Biopharmaceutical CMO Market by Source Outlook
11.3.6.2 UK Biopharmaceutical CMO Market by Service Outlook
11.3.6.3 UK Biopharmaceutical CMO Market by Product Outlook
11.3.7 France
11.3.7.1 France Biopharmaceutical CMO Market by Source Outlook
11.3.7.2 France Biopharmaceutical CMO Market by Service Outlook
11.3.7.3 France Biopharmaceutical CMO Market by Product Outlook
11.3.8 Italy
11.3.8.1 Italy Biopharmaceutical CMO Market by Source Outlook
11.3.8.2 Italy Biopharmaceutical CMO Market by Service Outlook
11.3.8.3 Italy Biopharmaceutical CMO Market by Product Outlook
11.3.9 Spain
11.3.9.1 Spain Biopharmaceutical CMO Market by Source Outlook
11.3.9.2 Spain Biopharmaceutical CMO Market by Service Outlook
11.3.9.3 Spain Biopharmaceutical CMO Market by Product Outlook
11.3.10 The Netherlands
11.3.10.1 Netherlands Biopharmaceutical CMO Market by Source Outlook
11.3.10.2 Netherlands Biopharmaceutical CMO Market by Service Outlook
11.3.10.3 Netherlands Biopharmaceutical CMO Market by Product Outlook
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Biopharmaceutical CMO Market by Source Outlook
11.3.11.2 Rest of Europe Biopharmaceutical CMO Market by Service Outlook
11.3.11.3 Rest of Europe Biopharmaceutical CMO Market by Product Outlook
11.4 Asia-Pacific
11.4.1 Asia Pacific Biopharmaceutical CMO Market by country
11.4.2 Asia Pacific Biopharmaceutical CMO Market by Source Outlook
11.4.3 Asia Pacific Biopharmaceutical CMO Market by Service Outlook
11.4.4 Asia Pacific Biopharmaceutical CMO Market by Product Outlook
11.4.5 Japan
11.4.5.1 Japan Biopharmaceutical CMO Market by Source Outlook
11.4.5.2 Japan Biopharmaceutical CMO Market by Service Outlook
11.4.5.3 Japan Biopharmaceutical CMO Market by Product Outlook
11.4.6 South Korea
11.4.6.1 South Korea Biopharmaceutical CMO Market by Source Outlook
11.4.6.2 South Korea Biopharmaceutical CMO Market by Service Outlook
11.4.6.3 South Korea Biopharmaceutical CMO Market by Product Outlook
11.4.7 China
11.4.7.1 China Biopharmaceutical CMO Market by Source Outlook
11.4.7.2 China Biopharmaceutical CMO Market by Service Outlook
11.4.7.3 China Biopharmaceutical CMO Market by Product Outlook
11.4.8 India
11.4.8.1 India Biopharmaceutical CMO Market by Source Outlook
11.4.8.2 India Biopharmaceutical CMO Market by Service Outlook
11.4.8.3 India Biopharmaceutical CMO Market by Product Outlook
11.4.9 Australia
11.4.9.1 Australia Biopharmaceutical CMO Market by Source Outlook
11.4.9.2 Australia Biopharmaceutical CMO Market by Service Outlook
11.4.9.3 Australia Biopharmaceutical CMO Market by Product Outlook
11.4.10 Rest of Asia-Pacific
11.4.10.1 APAC Biopharmaceutical CMO Market by Source Outlook
11.4.10.2 APAC Biopharmaceutical CMO Market by Service Outlook
11.4.10.3 APAC Biopharmaceutical CMO Market by Product Outlook
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Biopharmaceutical CMO Market by Country
11.5.2 The Middle East & Africa Biopharmaceutical CMO Market by Source Outlook
11.5.3 The Middle East & Africa Biopharmaceutical CMO Market by Service Outlook
11.5.4 The Middle East & Africa Biopharmaceutical CMO Market by Product Outlook
11.5.6 Israel
11.5.6.1 Israel Biopharmaceutical CMO Market by Source Outlook
11.5.6.2 Israel Biopharmaceutical CMO Market by Service Outlook
11.5.6.3 Israel Biopharmaceutical CMO Market by Product Outlook
11.5.6 UAE
11.5.6.1 UAE Biopharmaceutical CMO Market by Source Outlook
11.5.6.2 UAE Biopharmaceutical CMO Market by Service Outlook
11.5.6.3 UAE Biopharmaceutical CMO Market by Product Outlook
11.5.7 South Africa
11.5.7.1 South Africa Biopharmaceutical CMO Market by Source Outlook
11.5.7.2 South Africa Biopharmaceutical CMO Market by Service Outlook
11.5.7.3 South Africa Biopharmaceutical CMO Market by Product Outlook
11.5.8 Rest of Middle East & Africa
11.5.8.1 Rest of Middle East & Asia Biopharmaceutical CMO Market by Source Outlook
11.5.8.2 Rest of Middle East & Asia Biopharmaceutical CMO Market Phase
11.5.8.3 Rest of Middle East & Asia Biopharmaceutical CMO Market by Product Outlook
11.6 Latin America
11.6.1 Latin America Biopharmaceutical CMO Market by Country
11.6.2 Latin America Biopharmaceutical CMO Market by Source Outlook
11.6.3 Latin America Biopharmaceutical CMO Market by Service Outlook
11.6.4  Latin America Biopharmaceutical CMO Market by Product Outlook
11.6.5 Brazil
11.6.5.1 Brazil Biopharmaceutical CMO Market by Source Outlook
11.6.5.2 Brazil Biopharmaceutical CMO Market by Service Outlook
11.6.2.3 Brazil Biopharmaceutical CMO Market by Product Outlook
11.6.6 Argentina
11.6.6.1 Argentina Biopharmaceutical CMO Market by Source Outlook
11.6.6.2 Argentina Biopharmaceutical CMO Market by Service Outlook
11.6.6.3 Argentina Biopharmaceutical CMO Market by Product Outlook
11.6.7 Rest of Latin America
11.6.7.1 Rest of Latin America Biopharmaceutical CMO Market by Source Outlook
11.6.7.2 Rest of Latin America Biopharmaceutical CMO Market by Service Outlook
11.6.7.3 Rest of Latin America Biopharmaceutical CMO Market by Product Outlook

12. Company Profile
12.1 Lonza
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product  /Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Thermo Fisher Scientific
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product  /Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3  Cambrex Corporation
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product  /Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Catalent
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product  /Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Fujifilm
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product  /Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Siegfried Holding Ag
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product  /Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Samsung Biologics
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product  /Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 AbbVie
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Product  /Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Binex
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product  /Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Parexel International Corporation
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product  /Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
12.11 Others
12.11.1 Market Overview
12.11.2 Financials
12.11.3 Product  /Services/Offerings
12.11.4 SWOT Analysis
12.11.5 The SNS View

13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments

14. Use cases and Best Practices

15. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone